A composite prognostic model for overall survival (OS) based on residual cancer burden (RCB) and tumor-infiltrating lymphocytes (TILs) on residual disease (RCB+TIL) in HER2+ breast cancer patients treated with neoadjuvant therapy: a multicenter study
Titel:
A composite prognostic model for overall survival (OS) based on residual cancer burden (RCB) and tumor-infiltrating lymphocytes (TILs) on residual disease (RCB+TIL) in HER2+ breast cancer patients treated with neoadjuvant therapy: a multicenter study
Auteur:
Miglietta, F. Ragazzi, M. Fernandes, B. Griguolo, G. Massa, D. Bisagni, A. Bottosso, M. Porra, F. Gaudio, M. Iannaccone, D. Fassan, M. Lo Mele, M. Gasparini, E. Zarrilli, G. Coiro, S. Dore, L. Zambelli, A. Bisagni, G. Guarneri, V. Dieci, M.V.